Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:COVCVE:LTYNASDAQ:MDNANASDAQ:SVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOV(COV)$0.00$65.97▼$108.57N/AN/A3.88 million shsN/ALTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.67M0.01N/AN/A10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOV(COV)0.00%0.00%0.00%0.00%0.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOV(COV)N/AN/AN/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna Therapeutics1.1561 of 5 stars3.50.00.00.00.01.70.0SVASinovac BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOV(COV) 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideSVASinovac Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOV(COV)N/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ASVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOV(COV)N/AN/A0.00N/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ASVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOV(COV)N/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ALatest LTY, MDNA, SVA, and COV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/1/2025SVASinovac Biotech--$55.005/23/20255/23/20256/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOV(COV)N/AN/AN/ALTYLiberty Biopharma8.190.120.12MDNAMedicenna TherapeuticsN/A9.579.57SVASinovac Biotech0.0111.3911.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOV(COV)N/ALTYLiberty BiopharmaN/AMDNAMedicenna Therapeutics12.38%SVASinovac BiotechN/AInsider OwnershipCompanyInsider OwnershipCOV(COV)N/ALTYLiberty BiopharmaN/AMDNAMedicenna Therapeutics33.10%SVASinovac Biotech12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOV(COV)N/AN/AN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableLTY, MDNA, SVA, and COV HeadlinesRecent News About These CompaniesSinovac Responds To Vivo's Hostile Actions And LawsuitsApril 30, 2025 | nasdaq.comSINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo CapitalApril 29, 2025 | businesswire.comSinovac Biotech shareholder announces legal proceedings regarding boardApril 24, 2025 | markets.businessinsider.comSinovac Not To Meet Annual Report Filing Deadline With SEC As Auditor Resigns; Calls For New BoardApril 23, 2025 | nasdaq.comVivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board's Value Destructive ActionsApril 23, 2025 | businesswire.comSINOVAC Management Statement Regarding Auditor ResignationApril 22, 2025 | globenewswire.comSinovac Biotech Faces Audit Challenges Amid Board Legitimacy IssuesApril 21, 2025 | tipranks.comHeng Ren Urges Sinovac to Disclose Special Dividend Dates Proposes 41 Share Bonus PayoutApril 11, 2025 | msn.comSinovac BiotechApril 11, 2025 | vir.com.vnHeng Ren Urges Sinovac to Disclose Special Dividend Dates, Proposes $41/Share Bonus PayoutApril 11, 2025 | vir.com.vnHeng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the...April 10, 2025 | macaubusiness.comHeng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per ShareApril 10, 2025 | prnewswire.comSinovac Biotech to declare $55.00 per share special cash dividendApril 2, 2025 | markets.businessinsider.comSINOVAC Announces Decision to Declare Cash DividendApril 1, 2025 | businesswire.comSINOVAC Announces New Board Member and Chairman of the Audit CommitteeMarch 28, 2025 | businesswire.comSinovac shareholder urges transparency over COVID windfallMarch 24, 2025 | thepharmaletter.comHeng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholdersMarch 21, 2025 | finance.yahoo.comHeng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of TradingMarch 20, 2025 | prnewswire.comSinovac Biotech announces new board pursuant to privy council judgementMarch 1, 2025 | markets.businessinsider.comSinovac Biotech Restructures Board Following Privy Council RulingFebruary 28, 2025 | tipranks.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockWhy Call Option Traders Are Targeting This Dividend ETF NowBy Gabriel Osorio-Mazilli | April 21, 2025View Why Call Option Traders Are Targeting This Dividend ETF NowLTY, MDNA, SVA, and COV Company Descriptions(COV) NYSE:COVCovidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
